A redesigned cardio-metabolic capsule for blood sugar and heart health, at the same one capsule twice a day
November 4, 2026
| Engagement index (improved = 100) | Blood sugar (5 mechanisms) | Liver fat | Blood pressure |
|---|---|---|---|
| Current Formula | 7.9 | 66 | <1 |
| Market Comparator | 17 | <1 | 3.6 |
| Improved Formula | 100 | 100 | 100 |
Each product’s engagement on a mechanism as a share of the improved formula’s, averaged over the mechanisms in each group.
blood-pressure mechanisms scored, Market Comparator, a one-a-day blood-sugar capsule sold in India, averages 2.2 times its engagement.
The improved formula beats both on all 7 mechanisms and on all 4 customer outcomes scored (after-meal blood sugar, day-to-day blood sugar, blood triglycerides and liver fat). Averaged across the mechanisms, it engages more than 6.5 times as strongly as either product, in the same 100 simulated adults, at the same one capsule twice a day; neither product engages insulin signalling, blood pressure (ACE) or DPP-4.
It carries three actives with human trials on blood sugar or blood pressure that the current product lacks:
berberine [5, 6], chlorogenic acid from green coffee [8] and resveratrol [9], and keeps the pomegranate ellagic acid of BeepActive in a quarter of the capsule space.
Berberine comes as Berbevis, a phospholipid form. In the simulation it delivers 1.8× the blood exposure of plain berberine at the same dose and holds a 4.7× higher level through the night; in a human crossover trial the
same form gave 6.75× the total plasma berberine [7].
Of the five formulas shortlisted, this one leads on the most mechanisms (6 of 7). Green coffee is its strongest single contributor, but the formula beats green coffee alone on all 7 mechanisms, and without green coffee it still beats Current Formula on 7.
Why a stronger cardio-metabolic formula matters for these customers.
In India’s national survey of adults, 11.4% have diabetes and a further 15.3% have prediabetes [1]. Raised blood sugar travels with raised blood pressure and cholesterol, so a product for this customer is judged on all three: after-meal and day-to-day blood sugar, LDL cholesterol and blood pressure.
One capsule twice a day after food, 600 mg per capsule: the same daily routine as Current Formula.
| Ingredient | Per capsule | Marker per capsule | Role |
|---|---|---|---|
| Berbevis (Berberis aristata root, berberine phospholipid form) | 275 mg | Berberine 77 mg | Blood sugar and LDL cholesterol |
| Green coffee bean extract, 50% chlorogenic acid | 140 mg | Chlorogenic acid 70 mg | Blood pressure and insulin sensitivity |
| Pomegranate peel extract, 40% ellagic acid | 125 mg | Ellagic acid 50 mg | The ellagic acid of BeepActive, at a quarter of the mass |
| Trans-resveratrol, 98% | 60 mg | Resveratrol 59 mg | Blood sugar and insulin sensitivity |
| Product | Per capsule (label) | Daily routine | Simulated |
|---|---|---|---|
| Current Formula | BeepActive 500 mg (beetroot and pomegranate peel, ≥10% ellagic acid, ≥2.5% nitrate) + CoQ10 100 mg | One capsule twice a day | Ellagic acid, CoQ10 |
| Market Comparator | Mulberry leaf (Reducose, 5% DNJ) 200 mg, black seed oil 200 mg, gymnema 10 mg, bitter melon 10 mg, bilberry, alpha-lipoic acid, Berberis vulgaris, banaba and cinnamon 5 mg each, black pepper 2 mg, chromium 50 µg | One capsule a day | Every ingredient but chromium |
| Improved Formula | Berbevis 275 mg + green coffee 140 mg + pomegranate peel 125 mg + trans-resveratrol 60 mg | One capsule twice a day | All four ingredients |
[17].
Each product simulated in the same 100 adults, at its own daily routine.
Simulation basis
Population: 100 simulated Asian adults aged 40–65, half women, body-mass index 22–32, after food; each product at its label routine, simulated over four days and compared on day 4, once levels have settled.
Whole-body physiologically based simulation of every absorbed active, from release out of the capsule through the gut, gut wall, liver and bloodstream. Every identity is resolved through an authoritative chemical database;
Berbevis is simulated with its phospholipid and grape-seed carrier matrix.
Target activity is predicted by our activity models, trained on measured potency data, with measured values used where a molecule’s potency has been measured. Engagement is calculated on the unbound level at each target’s site (blood, liver, pancreas or gut wall), averaged over a full day and combined across every molecule acting on the same target; 20 targets are scored, covering blood sugar, lipids, blood pressure and drug-interaction safety.
All arms run in the same simulated adults: the improved formula, Current Formula, Market Comparator (one capsule a day; grades its label leaves out set at the common high commercial grade), four shortlisted alternative formulas, the improved formula without green coffee, green coffee alone, and Berbevis against plain berberine at the same dose.
Every ingredient with a defined marker is simulated, including Current Formula’s CoQ10 and each of Market
Comparator’s herbs. Two are not: chromium, a mineral, and BeepActive’s nitrate, a simple inorganic ion, whose effect is taken from the published trials cited.
Berberine is also scored in the gut fluid, at the glucose transporter SGLT1 on the gut lining, as a separate scale.

| Product | Molecule | Per day | Reaches blood | Day-4 peak | Lowest level of the day |
|---|---|---|---|---|---|
| Improved Formula | Berberine | 154 mg | <0.1% | 1.28 ng/mL | 0.13 ng/mL |
| Improved Formula | Chlorogenic acid | 140 mg | 28.0% | 676 ng/mL | 60.7 ng/mL |
| Improved Formula | Ellagic acid | 100 mg | 36.9% | 784 ng/mL | 145 ng/mL |
| Current Formula | Ellagic acid | 100 mg | 25.3% | 590 ng/mL | 88.5 ng/mL |
| Market Comparator | DNJ (mulberry) | 10 mg | 52.4% | 73.3 ng/mL | 0.11 ng/mL |
| Market Comparator | Thymoquinone | 2 mg | 47.7% | 32.6 ng/mL | 0.0044 ng/mL |
Median blood levels over four days at each product’s own routine. The improved formula’s two daily capsules keep each active in the blood through the day, where a once-daily capsule falls to near zero before the next dose.
Engagement of each mechanism on day 4, indexed to the improved formula = 100.

| Mechanism | What it acts on | Improved | Current Formula | Market Comparator | Main contributors |
|---|---|---|---|---|---|
| Insulin sensitivity | PTP1B, the brake on the insulin receptor | 100 | <1 | <1 | Chlorogenic acid 100% |
| Blood pressure, renin– angiotensin route | ACE and the AT1 receptor | 100 | <1 | 4 | Chlorogenic acid 95% |
| Incretin support, in blood | DPP-4, which breaks down GLP-1 | 100 | <1 | <1 | Resveratrol 61%, Chlorogenic acid 34% |
| Incretin support, at the pancreas | GLP-1 receptor on insulin-releasing cells | 100 | 7 | 37 | Resveratrol 61%, Chlorogenic acid 34% |
| Glucose uptake from the gut | SGLT1 at the gut wall | 100 | 16 | 41 | Chlorogenic acid 40%, Resveratrol 35%, Ellagic acid 23% |
| Gut hormone signalling | GPR119, TGR5 and FFAR2 on gut hormone cells | 100 | 17 | 8 | Chlorogenic acid 44%, Ellagic acid 39%, Resveratrol 16% |
| Liver fat-making and cholesterol synthesis | ACC and HMG-CoA reductase | 100 | 66 | <1 | Chlorogenic acid 44%, Ellagic acid 41%, Resveratrol 12% |
| Outcome | Through | Improved | Current Formula | Market Comparator |
|---|---|---|---|---|
| After-meal blood sugar | GLP-1 receptor | 100 | 7 | 34 |
| After-meal blood sugar | DPP-4 | 100 | <1 | <1 |
| After-meal blood sugar | SGLT1 | 100 | 17 | 53 |
| After-meal blood sugar | GPR119 | 100 | 21 | 12 |
| Day-to-day blood sugar control | GLP-1 receptor | 100 | 7 | 37 |
| Day-to-day blood sugar control | DPP-4 | 100 | <1 | <1 |
| Day-to-day blood sugar control | SGLT1 | 100 | 16 | 41 |
| Day-to-day blood sugar control | GPR119 | 100 | 20 | 8 |
| Blood triglycerides | PPAR-alpha | 100 | 3 | 16 |
| Fat stored in the liver | ACC, the liver’s fat-making enzyme | 100 | 67 | <1 |
chlorogenic acid 56%, resveratrol 27% and ellagic acid 16% is the average share of its engagement each molecule carries.
The blood-pressure benefit of chlorogenic acid rests on its clinical trial [8]; the renin–angiotensin row shows the simulated engagement of that route.
Berberine’s best-documented actions, switching on the cell’s energy sensor AMPK [16] and raising the liver’s
LDL receptors [11], work through the cell’s energy state and gene activity rather than by binding a single target, so they are carried by its clinical trials [5, 6] rather than by these rows.
Five formulas were shortlisted at the same capsule size and routine. Each is indexed to the chosen formula
= 100.

| Formula | Per capsule | Matches or beats Current Formula | Best of the five | Average index |
|---|---|---|---|---|
| Chosen formula | Berbevis 275 + green coffee 140 + pomegranate 125 + resveratrol 60 mg | 7 of 7 | 6 | 100 |
| Plain berberine HCl version | Berberine HCl 250 + green coffee 140 + pomegranate 125 + resveratrol 60 mg | 7 of 7 | 1 | 99 |
| Pomegranate + berberine | Pomegranate 125 + berberine HCl 400 mg | 7 of 7 | 0 | 22 |
| Without pomegranate | Berberine HCl 375 + green coffee 140 + resveratrol 60 mg | 6 of 7 | 0 | 79 |
| Keeps BeepActive | BeepActive 250 + pomegranate 63 + berberine HCl 200 mg | 7 of 7 | 0 | 22 |
(average index 79).
The chosen formula against the same formula without green coffee, and against green coffee extract alone.

beats Current Formula on 7 of 7. Green coffee extract alone reaches an average 31%, and the full formula beats it on all 7.
Part of that gain is absorption: in the formula, 28.0% of the chlorogenic acid reaches the blood against 15.4% when green coffee is taken alone, which the simulation attributes to berberine slowing chlorogenic acid’s breakdown.
Berbevis against plain berberine at the same 77 mg of berberine per capsule, twice a day.
| Reaches blood | Day-4 exposure (AUC) | Lowest level of the day | |
|---|---|---|---|
| Berbevis 275 mg | <0.1% | 13.2 ng·h/mL | 0.11 ng/mL |
| Reaches blood | Day-4 exposure (AUC) | Lowest level of the day | |
|---|---|---|---|
| Plain berberine, same 77 mg | <0.1% | 7.37 ng·h/mL | 0.023 ng/mL |
| Berbevis advantage | 1.7× | 1.8× | 4.7× |
The phospholipid form releases berberine more steadily and protects more of it through the gut wall, so the simulated exposure is 1.8× and the lowest level of the day 4.7× that of plain berberine. In people, two tablets of the same berberine Phytosome (376 mg berberine) gave 6.75 times the total plasma berberine exposure of 500 mg berberine chloride (452 mg berberine) in a randomised crossover in 12 adults [7].
Berberine is poorly absorbed, so most of each dose stays in the gut [7]. Plain berberine floods the gut fluid soon after each dose and is gone within about 2 hours; Berbevis releases it gradually and keeps it at active levels for about 8 hours per dose. Scored at the glucose transporter SGLT1 on the gut lining, which faces the gut fluid, that longer coverage gives the improved formula the highest engagement of any product.
| Product | Berberine in gut fluid, peak | Hours per dose at active level | SGLT1 engagement in the gut |
|---|---|---|---|
| Improved Formula | 97.4 µmol/L | 7.7 h | 0.64 |
| Berbevis 275 mg alone | 88.9 µmol/L | 7.7 h | 0.64 |
| Plain berberine (77 mg) | 922 µmol/L | 1.9 h | 0.15 |
| Market Comparator | 0.7 µmol/L | 0.0 h | 0.04 |
| Current Formula | no berberine | — | 0.006 |
Gut values are scored on the dissolved concentration in the gut fluid and compare products with one another on this scale only; they are not combined with the blood-based results above.
People managing blood sugar and heart health often take other medicines. Two questions: can the formula raise the levels of other medicines, and can other medicines change the formula’s levels?
| Molecule | CYP3A4 | CYP2C9 | CYP2C19 | CYP2D6 | CYP1A2 | Gut CYP3A4 | Gut P-gp |
|---|---|---|---|---|---|---|---|
| Berberine | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 14.0 flag | 61.2 flag |
| Chlorogenic acid | 0.01 | 0.01 | 0.02 | 0.005 | 0.03 flag | 0.75 | Not an inhibitor |
| Ellagic acid | 0.003 | 0.005 | 0.01 | 0.002 | 0.24 flag | 0.17 | Not an inhibitor |
| Resveratrol | 0.01 | 0.07 flag | 0.13 flag | 0.005 | 0.02 | 0.13 | Not an inhibitor |
| Molecule | CYP3A4 | CYP2C9 | CYP2C19 | CYP2D6 | CYP1A2 | Gut CYP3A4 | Gut P-gp |
|---|---|---|---|---|---|---|---|
| Whole formula | 0.03 flag | 0.09 flag | 0.16 flag | 0.01 | 0.28 flag | 15.0 flag | 61.2 flag |
Blood: unbound peak level divided by the predicted inhibitory potency; at 0.02 or above a clinical interaction study is indicated (ICH M12). Gut: the simulated peak dissolved small-intestine concentration divided by the potency; threshold 10. Whole formula: each molecule’s ratio added per enzyme, since inhibitors of the same enzyme add up.
The whole formula reaches the screening threshold for blood CYP3A4, blood CYP2C9, blood CYP2C19, blood CYP1A2, gut CYP3A4 and gut P-gp. Berberine accounts for gut CYP3A4 and gut P-gp, in line with what has been measured in people: berberine taken at 300 mg three times a day for two weeks slowed CYP2D6, CYP2C9 and CYP3A4, raising exposure to the CYP3A4 test drug midazolam by 40% [13]. Resveratrol accounts for blood CYP3A4, blood CYP2C9 and blood CYP2C19, in the same direction as a study in people in which 1 g of resveratrol a day for four weeks slowed
CYP3A4, CYP2D6 and CYP2C9 [18]; the formula provides 118 mg a day. Chlorogenic acid (blood CYP3A4) and ellagic acid (blood CYP1A2) account for the rest, as model predictions; Current Formula’s ellagic acid already reaches the blood CYP1A2 threshold today (0.18). The label should advise people taking prescription medicines, particularly those cleared by these enzymes such as several statins, blood-pressure and diabetes medicines, to consult their doctor, and a laboratory inhibition study of the finished capsule would set the exact margins.
Can other medicines change the formula’s levels?
† Published data [15]; other calls are model predictions of the enzymes and transporters that clear each molecule. A medicine that blocks one of these routes can raise that molecule’s level.
| Molecule | CYP3A4 | CYP2C9 | CYP2D6 | UGT | P-gp |
|---|---|---|---|---|---|
| Berberine | Yes | No | Yes | Yes | Yes† |
| Ellagic acid | No | Yes | No | Yes | No |
| Chlorogenic acid | No | No | No | Yes | No |
| Resveratrol | No | Yes | No | Yes | No |
All four ingredients are on FSSAI’s permitted lists for health supplements [14]. Berberis aristata root or stem extract is listed in Schedule II with a permitted range of 0.5–1 g a day; two capsules provide 550 mg of Berbevis, Indena’s recommended dose [17]. Standardised green coffee seed extract, pomegranate fruit, seed or skin extract and resveratrol are listed in Schedule III (entries 83, 155 and 159), which sets no quantity for them. Because berberine affects the clearance of several medicines, the label should carry a caution for people on prescription medicines, and for pregnancy and breastfeeding. The regulatory team should confirm the final label against the current schedules.